TargImmune

TargImmune Therapeutics AG is a private Swiss-based biotechnology firm focused on drug development using novel targeted immunotherapies. The company's principal technology is the CTPIC technology platform that utilises a proprietary non-viral vector to target and destroy cancer cells that over-express certain receptors.